Prognostic significance of novel inflammatory markers in extensive-stage small-cell lung cancer

Yılmaz, Hatice; Yersal, Özlem

doi:10.4103/jcrt.jcrt_1937_21

Cited by 8 publications

(10 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, 11 were not suitable for inclusion criteria. Finally, we identi ed 31 studies from 29 articles published between 2020 and 2023 [14,15,16,17,18,19,20,21,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44]. The ow diagram of the literature search was shown in Fig.…”

Section: Search Resultsmentioning

confidence: 99%

Prognostic value of lymphocyte-to-C-reactive-protein ratio in cancers

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Systemic inflammation and immune nutritional status affect tumor progression and patient survival. Lymphocyte-to-C-reactive-protein ratio(LCR) as inflammatory immune index has been reported to be associated with prognosis of various cancers. However, the results are controversial. Therefore, the aim of this study was to comprehensively evaluate the clinical value of LCR in cancers through a meta-analysis. Methods A comprehensive search of relevant studies was performed by scrutinizing the databases until March 31, 2023. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate overall survival (OS), disease-free survival (DFS), recurrence free survival (RFS), progression-free survival (PFS) and cancer-specific survival (CSS). Results A total of 31 studies from 29 articles involving 11429 patients were included in the study. The pooled analysis showed that patients with high LCR was significantly associated with favorable OS (HR: 0.51,95% CI:0.48–0.55),DFS (HR: 0.55,95% CI:0.43–0.70),RFS (HR:0.57,95% CI:0.48–0.67),PFS (HR: 0.50,95% CI:0.27–0.92) and CSS (HR:0.53,95% CI:0.42–0.67).Sensitivity analysis confirmed the reliability of these results. Conclusions LCR can be used as an effective prognostic marker in cancers.

show abstract

Section: Search Resultsmentioning

confidence: 99%

Prognostic value of lymphocyte-to-C-reactive-protein ratio in cancers

Liu

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…In a study by Yuan He et al 11 consistent with the findings of previous studies, LCR was determined as an independent prognostic marker for both PFS and OS, whereas decreased LCR was found to be a poor prognostic marker. A study by Yılmaz H et al 12 which is the first publication in our country demonstrating the prognostic significance of novel inflammatory markers in extensive small cell lung cancer, showed that LCR is an independent prognostic marker for both PFS and OS. In this study, PFS (p <0.001) and OS (p < 0.001) were found to be longer in the patient group with high LCR than in the low LCR group.…”

Section: Discussionmentioning

confidence: 99%

“…11 Another study reported the prognostic significance of many inflammatory markers in extensive-stage SCLC. 12 A decrease in lymphocyte/ monocyte ratio (LMR) was found to be a poor prognostic indicator in extensive-stage SCLC. 13 Despite growing evidence of the impact of these inflammation-based scores on the prognosis of SCLC patients, there is limited information on the prognostic significance of the novel parameters.…”

Section: Introductionmentioning

confidence: 99%

Yaygın evre küçük hücreli akciğer kanserinde lenfosit/C-reaktif protein oranının prognostik önemi

ÖZTÜRK ERGÜR,

ÖZTÜRK,

UZEL ŞENER

et al. 2023

Journal of Medicine and Palliative Care

View full text Add to dashboard Cite

Aims: We aimed to investigate the pre-treatment prognostic significance of lymphocyte/C-Reactive protein ratio (LCR), one of the inflammatory factors, in patients with extensive-stage small cell lung cancer (SCLC). Methods: Medical records of 514 patients who were diagnosed with extensive-stage SCLC between 2010 and 2020 were examined retrospectively. LCR was calculated using the blood test results prior to chemotherapy. Results: The mean survival time for extensive-stage SCLC is 6 months (5.3-6.7). A statistically significant difference exists between limited and extensive stages in terms of median overall survival (OS) (p

show abstract

“…In our study, we did not investigate advanced stages of lung cancer, but as we can see, results in advanced stages were similar to those in early stages. In patients with advanced NSCLC, lymphocyte-to-C-reactive protein ratio and SIRI were identified as independent prognosticators for both PFS and OS (P < 0.001, P < 0.001; P = 0.002, P < 0.001, respectively) [27]. Another group of investigators found that increased levels of SII were predictors of worth prognosis in patients with advanced NSCLC.…”

Section: Figure 1 -Roc Curve Analysis For Optimal Cut-off Value Of In...mentioning

confidence: 98%

Inflammation Indexes as Predictors of Recurrence in Patients With Surgically Resected Non-Small Cell Lung Cancer

Smorodska

Moskalenko

Kononenko

et al. 2022

EUMJ

View full text Add to dashboard Cite

Introduction. Prediction of lung cancer recurrence is one of the most urgent problems of modern oncology. Scientists are trying to find independent predictors that will help intensify, personalize the patient's treatment, and prevent the disease relapse on time. The study aimed to find indicators of inflammation that could be independent predictors of disease recurrence in patients with surgically resected non-small cell lung cancer. Materials and methods. The study was conducted retrospectively. The study group included 104 patients with non-small cell lung cancer who received surgical treatment and adjuvant chemotherapy or chemoradiotherapy from 2014 to 2018 at the Sumy Regional Clinical Oncology Dispensary. Based on the results of the blood count tests, the inflammation indices were calculated before chemotherapy or chemoradiotherapy and one month after their completion. Systemic inflammatory response index (SIRI), systemic inflammatory index (SII), neutrophil/lymphocyte ratio (NLR), platelets/lymphocytes ratio (PLR), lymphocyte/monocyte ratio (LMR), monocyte/lymphocyte ratio (MLR) were calculated. Using ROC analysis, cut-off points were found. Cox regression was used to find independent predictors of lung cancer recurrence. Results. During the observation period, relapse of the disease was recorded in 42 (40.4%) patients. The average recurrence-free survival was 56.3 months, range of 4–84.0 months (95% CI = 46.866–65.683). Before chemo- or chemoradiation therapy, the cut-off points for NLR1, PLR1, MLR1, LMR1, SII1, and SIRI1 were 1.80, 126.35, 0.22, 4.80, 521.22 and 0.96, respectively. Cut-off points for NLR2, PLR2, MLR2, LMR2, SII2, and SIRI2 at stage one month after completing courses of chemotherapy or chemoradiotherapy were 1.33, 153.80, 0.26, 3.98, 450.10 and 0.82 respectively. According to ROC analysis, only PLR1, SII1, LMR1, and LMR2 indices are reliable and can be used in further Cox regression analysis. Univariant Cox regression showed that LMR1 and SII1 were significantly associated with disease recurrence. Multivariate Cox regression identified SII1 as the only independent predictor of disease recurrence. Conclusions. Among numerous inflammation indices as an independent predictor for disease recurrence in non-small cell lung cancer patients who received surgical treatment and chemotherapy or chemoradiotherapy, only systemic inflammation index (SII1) at the stage before chemotherapy or chemoradiotherapy can be used. Indicators above 521.22 could be a predictor of high-risk recurrence of lung cancer.

show abstract

Prognostic significance of novel inflammatory markers in extensive-stage small-cell lung cancer

Cited by 8 publications

References 26 publications

Prognostic value of lymphocyte-to-C-reactive-protein ratio in cancers

Prognostic value of lymphocyte-to-C-reactive-protein ratio in cancers

Yaygın evre küçük hücreli akciğer kanserinde lenfosit/C-reaktif protein oranının prognostik önemi

Inflammation Indexes as Predictors of Recurrence in Patients With Surgically Resected Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About